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The devclopl1lcnc of the ceph3losporin.~ III the last 40 years
exel1lph6~ many of the issues en ounten::d during the complex
proce~ of drug d<:veJopmem. The mould Ct'p!lIl/OSpOrillll/
lIilTlIl(l/lil/lIl tho t was the original starting poim for the
<:phalosp nn anoblOtic serie~ was di covered in 1948 in
3.l'dU1J3. but II was not until 1953 that cephalo porlll was
dl.~ov<:red. by Florey's group at Oxford. as a nunor component
of the mixrut<: of antibiotics that thjs mould produces.
ephalosporin C has only modest antibacterial activiry and
wa n t made in quantiry until 1960 when Morin et al. at
the Lilly laboratories described a new procedure for obtaining
7-A A. This development paved the way for the future
devdopmem of large numbers of semisynthetic molecules.
The omewhat unprepos cssing antibacterial p tency of
ceph.losponn 15 rypical ofactivlry that is often ~c:en in novel
rnoh:cuJes derived from microorganisms. The interest in novel.
nanlTaUy occunng agents lies often in the 'scaff. lei' that the
natural molecule provides. uch complex starting points
would be very difficult and expensive to make by total
synthesis yet can be made relaovely easily by fennentaoon
once trall1 e1e tion and growth conditions are optimized for
mdustrial- calc production. ephal sporin w not nl;\de by
t tal syndlesl5 unru 1965. when Woodward described d,e
synmesi in a obel lecnlre.
Imerest in cephalosporin 111 the e1Irly 1950s has to be
placed 10 the comext of the medjcal needs of that ome. By
1952, 90% of staphylococci in London hospitals wc:re already
pemcillin resist.lm and me newly available nl;\gic bullet.
peniciUin, 10 ked under ducat. ephalo porin was resist.1nt
to penicillinase and so offered promise. H wever. by 1961.
pemcilllO i elf had been modified to give new emi ymheti
I'erucillins. cloxacillin and methicillin. both f which were
more s~ ble to penicillinase and active agajllSl tophy/orofClI
O/lrtus. The role for cephal sporin therefore looked
uncertain but the basic's afrold' had two points where
chemical modification could be made and thIS £fered the
possibility of increasing activiry again t Gram-negative organ-
isms. The even-position side chllin had proved difficult to
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cleaw bue. once 7-A A becamc available. numerolU novel
cephaJo porim were preparcd by re-acylati n and the first
cephalosporim, cephalothin nd cephaloridine. r('ached the
market in 1964. Thi proce had taken more than 10 years
widl most of the time devoted to chemical synthcsis and scale-
up with a relatively brief c1il1lcal progr:Ul1.me.
DISCOVERY
In the last 50 years, new 'scaffolds' have been sought
a iduously and many other antibiotic series such as the
tetracyclines. amin g1yco ide. oxazoliclinone and Strl.·pto-
gramins h. ve e.merged. Se3.l'crung for soil or odler cnviron-
mental strains producing novel molecules re ults in high
attrition rate and crcening teclmiques need to be high
throughput. Finding active leads is relativel easy but
cha.ractenz.IIlg them cau be a lengthy pro ess. In the
cephalosporin serie. ull char:lcterization 0 the mode of
action of thc ~-lactam series wa.~ not done until 1975 when
Drian Spratt showed the rclevan e of penicillin binding
proteins. Thi Wa! more than 35 yearl; after the discovery
and c1illical use of penkillin.
Nowadays. comblllatonal chen1l5try techlllques and genetic
technique should speed the process ofpreparing cmisyndleoc
or fully synthetic m lew! bccau e a wide Tange of chemical
options can be explored quickly and on very small sc.le so
that \ hen larger cale chenmtry begins, option h ve been
defincd more tighdy.
Attrition rate for any drug development programme are
high, typically one in 5000-100 0 at the e1Ir1y developmcnt
stagc. moving to one in 250 during pbase III studies and one in
five at posrmarkenng.
The original patents for cephaloridine and cephalothin date
from 1954 and smce that rime at least another 250 patents
have been filed, covering cephalo porins. intemlcdiates and
pro e s patentS. The c underpin the market use of these gents
and represent a very important Sector of the intellectual
property of the phamlaceutical indusrry.
SCALE -UP
In the Story of mould to drug, the scale-up of production to an
industrial cale capable of supplying many.-ronnes per allnum is
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a cnnc.1 pan (thl' enoeavour. TIllS part of the pro e~s.
together \ Ith phanllaCl'UlICal torl11ulanon. IS arguably the
Illmt IInpOrtdlll o( Ihe klll~ of the IIldllmy, yet it IS often an
UII. cknowledgcd part (Ihc pro e ~.
. calc-III' 1ll.1V IIwolve ft:nnelllallon, as III the ca~e o( the
c('ph;llmpnnm where typlcall ccph. lo~ponn i~ prepared III
lOll UOll Iltcr balches and converted to 7-A 'A in a wry rapid
procc~~. CI11I-S nthelJc Illolccnle then rl'qmre chcnllcal
1I10dlfi anon Via, sene o( SI(,PS. III sOllle caSl' , pamcular
proCC~\CS Illay Ill' needco to gcnerate a lom1 ofa Illolecule Ihat
1\ particularly ~lIlt,lble tor (oml\lbnon or aCllVlty. x:trnples
Incllllk dllral . ynthcse\ and thc producnon f particular tom1s
to ('I1\lIre <lablhev a III thc ca e of the penl.lhydralt: crySlalhne
toml o( cettazldllnc. The drug tonn call b(' cntically
IIllpOnall1 In delcfl1llnlllg how an agcnl is U ('0 dlllic,llly
and Ihere C,IIl be kev dll crcnccs bClween ~enenc :lgent alld
the 1I1110\'ator ( nIlS that denve (rolll dltTl'rent Illclhods of
11lanuljcrun: II 1\ usual f I' any hallge IJ1 process {Q be
reg1\lered and wherc ,IllY hall~l' In Il11pUnllCS or ton11 arc
hown. a l11anulacnlrer Illa need to dClllon Iratc addmollal
lClX.lcologl aJ or bloequl\'alcnc(' ,bta as a III II II IllU 111 , III
addmoll to roullnc chcnncal and pllJrlllaceunol labihty
data. All Ihese IlIlallCn o( producnon and 10nllulalJOn arc a
III ~or p, n o( thl' work of thc IIldust . .eltm!: these aspects
(lptlltllzed cOlllnbule\ to 0 er."1 devdopmel1l {line :lI1d co ts.
At every \tagl' speClli 'kl1ll\v Ill)W' 1\ o(ten II1volved and '0
pfOC':S' patcnnng IS .1 h' , 1'.1fl of thc tot,,1 IIHellecl\lJl property
associated with .1n . dntg.
I'ron's, chcIIIIStry IIlml Iso be conducl.:d under 'onditioll
that rc salt: ,lI1d l'nvlronJ11ell[all appro) nate, so method
mU'1 l.lkc .1CCOlIOl of thesc I1ccd-'. Operarors at both primary
.llJd ,econd.lI, k'vd procl'SSlng llJay Ilc('d lU be procccted from
d.llly exposure to a drtl~ lhat mlghl bc u,ed 0111 for hon
pellod-, III pallenL.s. Ther.: Illa aho be ~pel:llic 1.'SlIe of
hypersen~ltI211l!l pOlo:ntlal or othcr risk, th.1t no:ed to be
1Illl11mlZcd via ellvlrolUlICI1l.11 de Igll or 111 exc('ptJonal
Clrnllmt, nee prOtective clothing 'or opcr,llOr. .
FORMULATION
Phaflll.lceutlc~1 f nllul.1lI0n 1l1\'olves en. unng that thc drug
can bc dehvere:d ppropnately to the requl Ite Itc r ,ICnOIl 111
111311. In addition. the drug mu t be pre l'llll'd III SUItable
pack.lglng to ~ rantee: a table ano et CCtl e produci
throughout a <tatl·d helf-lJlc of an adcquatc dur,lIoll. o(tell
scvCfal years.
I rtlg fmll , nd fomlulatlon can prolounJly afJi:cI bioav.11i-
ahlhty In man. .eph.losponm \\ ac a\·all. ble IIl1tlally ollly by
II1Jcctlon . nd w1th a relatlvcl hort half-hti.. , meanll1g thaI
Illultlplc dally doscs were: nc('ded. cphalodlln and cefrn, x-
Olle represclll eX"trl'mc III thl' ceph I sponn senes bc aus('
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cephalothin 1\ readily dc-a erylated hy e,terase activ1ry in man
to the Icss aerive de -aCt:tyl tOrlll, re ultlllg In an c:Il1ll1nanOn
h,lf-lifc f JU t Icss th.1n 1 hour eftna: one III COI1lT:l t. b
1110dlficatlon of the 3-1'0 lti 11 \Ide chall1, can bc gwen once or
tWice dally becallse lhe:r(' LS no Ill. tahlhty and lhe ehnullallon
half-life I. 6-8 h.
AII1 ng the or.lly abs rbed cephalo ponns. thc earlie t
agent cphalexlIl and It!. do ely related al1alo~, ccphradllle,
cef., I I' and cefprolll, arc all actl\'dy ab 'orbed be JU c Ihl'Y
arc recogmzed by di-anullo-acld uptake palhw,l)' III the
I1llc:511l1al l11ucosa. This result. 111 almo.t complete or.,1
absorption, Wld1 blood levels <Imilar to lhosc achlcved by
Injection of IIII.' ~ame agent 111 contraSI. the latcr geller:anom
r rcphalosponns have proved nlorl' ddT. ult to f0rt1111late for
oral IISC and. III l11any cases. prodru~ havc been madc. ftl'n
uSlI1g bulky esters to make the III leculc\ m re Itpoplllhc ~nd
hen 'C able to crm~ the IIllestll1al Illucma after remov~1 01 thc
e,tcr group by e\ll'raSe actlVlty 'cfuroXlme: axcnl IS 3n
ex, mplc of rim type of agcnt, and I absorbcd folJowlll~
hydrolysl by a specific e\tera e. Il~ lomlllianon for pedl~lnc
use: proved unu~ual be au~e thc llIolecule, likl' mallY p-
LlClalll • h s a biller tastl' a~. p wdcr. To overc lIle thl . the
cefuroxllne axetll II wax coated hd<lre belllg lomllllatcJ Jrl a
frUlt-/lIvoured ~lISpenslOn
Issues of olubulty and stablhtv are a particular c nCI'm tor
all cephalosponm and mdeed most p-Ia ,m anllblOtic~
bec~lIse the c compoul1ll, tend to he rebtl\'e1y lImt hie: m
the pI' 'sell e of m 'lIlrc. Thl me n\ lhat pack, glllg nce.is to
he mOisture proof and m I ture cOIlle:m oftcl1 ne:eds to be
comrolkd dunng production pro eS5e\.
SAFETY STUDIES
The CCph:llosporlll senes h~\ been r<:lllark~bly rce fTom major
tOXI it ISSUCS, dlle 111 part 10 the hi >h d<:grce: f selectlVlry of
thc mode of aCllon. Man has no coullterpm co d1C peru IlIm-
bllldlllg 1'1'0[('1115 of thc bactcflal cell wall. n 1 0 the p-l.1Ct3ms
arc hlghl ~clecllve. Thl~ lu~ mealll d1 t III 5t cephalosp rtI
have b('l'n used m patients of all age, II1dudmg, 111 many
a,el, n('()natl'\. They .rc \uggested (or II c: III m st
therapeutIC ,nd prophylacnc lI11iJc3non~. Use II1dudo
m 'nmb'ln, and severe II1lectlons 111 ncutropelll s wherc
cphalosponns alonl' and 111 cOlllbll1:mon have bccn part oi
'1-:01<1- ·tandard' IrearmCIll rc:h'lmc, tor the I t 15-20 can.
The earhcst compounili. ceph,lou,1I1 and ce:pha.londmc,
ral cd ome concerns bccau e the werc elullInated b tubular
secretion, and in very high J s~ nephI' tOXI Il)' \\1:1 a
concern H we er, laler COlllp und overcame: dll\ Issue. TIle
ccphalo. ponm I encrrate nssues and n suc tlUlds dfe lively,
II1cludlllg bone, ,md they eros intlamcd meninges makmg
t1wlll all II1lport:lllt opoon 111 Illelllngltl!.
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CUNICAl STUDIES
he cephalosponns have been cxten ively ,tllched In chmcal
mats worldwide. The regulatory environmcnt ha~ bccome
more demandtng In the I., t 40 years since thc inrr duction of
cephalothin. For antibi ti" t day. there. re ome pani ular
I5SU~ th:u regulators . nd mdu. try alike are wrestllllg with
These relate to problems 0 demonstrating efficacy of new
. gents ag:tlll\t emerging and n:mtant strams. In the last 20
years. we have seen me emcrgence of several new pathogen
u h :IS ugfllllrlla pp. r HcI;((I!>a(lu pylori. whilst illUlluno-
compr mized paoents may be l1Ie infected witll org n' illS
hitherto c:on'ldered to be of linllted patll gcmc potencial. In
these chlllcal , enari s. tlle rclatiomhip f the pathogen and
pathology is not nece sarily as obvious as In some classical
Inlecool15 the past. In the c e of resIstant strail15 uch
pel1lcJ1lin-reSlStant pneum OCCl (PRP) I' methicillin-
resJ tlllt . t1I1I'l'II (MR A). me pathological ignificance is not
always traightforward. Addition lIy in the con tra.ined
environment 0 chnical tudie. new resistances Ill:ly be poorly
represented among patien ,ho are recruited to trials. and
consequcntly efficacy cannot be delllon trated agal1151 reSlSt:lI1t
ISolates at levels tlut are nausocally meamngful. 0 ne'
algonchllls are needed for mal designs that asses, effica y
against resist nt pamogel15. In reasingly, pliannacokinetic
togetller with pharmacodynamic parametel1l ale being used
to UpPO" efficacy agalllst ne\ resinan e n1:1Ike . Unlcs the e
ryp of da are u ed as a urro teo drug development to
.I1S\ver the needs ofbactecial resistance wul nOt be possible and
by virtue of their uperior generatJ n turnover, resistant
bactena \ ill continue to gain cendaocy.
CEPHAlOSPORINS IN THE MARKETPLACE
The cephalosporin series of antibiotic has been very succe ful
in global use and the f}-laCtalll ag nrs Ie till a major group.
This IS probably due to the specificity of tlle m de f acn n of
mese gen • which is still a distinguishing f, lUre and real
trength of die eries. The cephal poans have c nllibuted to
both h pital no conmlumty medicine fc I' me I . t 45 yc:a11l
and meir development h mirrored medical need~ dunng that
time. The 'ries h:lS sh wn i elf able to encompa s new
resistance. particularly f}-l:Ictam;\ses. In the 197 the
Iscovery 0 the oxime moiety contributed particularly in this
regard and ttus h been used In most cephalospori since the
discovery of cefuroxime. he d lin n of the amin t1ti lolyl
nng at me even position in cefotaXime by Rou c1-Uclaf.
III Iked nother key milestone nd I -fold improvement in
potency against r;Jm-negati e Isolate. hi ,Ide chain has
been extensively used in almost all third-generation oral and
IIljectable molecules. Efficacy ag;u.ost Pst'uncl/110l/aS aerugillosa
had always seemed elusive in the cephalosporin series until tlle
I. tc [9705. when cdswodin. tbe narrow peetnJm agem. and
cc:ftazldll1lC, a carbox')'alkyl Xlme, were d cobed. The latter
molecule has been Widely u cd nd c nonues t set the
standard for ~-I:ICl. ms in temlS of Iltip eud mon I actlvity.
Two llletholClIlIes with novel qu tern. ry • Illlll ilium 3-
ubsolUen ,cefpirome and ce eplme. have also been marketed
subsequently and show chnical efficacy equlvalem to that of
ceftazidime. More recentl . attempts have been made to
improve. nop cud mOllal activity by u ing cateehollll.imi or
cate holie gr up. t the seven or three positi n in order to
a hicve active upt:lke f the ceph. losporins via iron-tran port
mechani ms. The oncept was showu t be vahd b several
groups ,vithm the ph nnaccutical mdustry but no develop-
ment candJdate emerged, p rh:lps bealU e of i ue of toXlClty.
In me 1:1. t year c:veral ephalosp ril15 ,\;m enhan cd activity
ag,ufl5t MR A have been described. The e agents, exemplified
by a R che compound. R 63-9141, h. ve nsiderably
unproved a tivity again t MR A compared with ther
cephalosponns and It remains to be: seen s hether this
Import.lnt group of organisms can be encompas~ed in the
ce:phalosp nn pecrrum.
CEPHAlOSPORINS FOR THE FUTURE
an me cephalospoon series continue to meet medical needs?
urrently the: mo t pr ing lTledical i uc in infcctlons in
critical C re include vancomycin-r . tant enter ci (VRE).
p nicubrly Eurl!l'(){o«(Ij$ jarol/m. Th e uail15. re particularly
intractable and at olien multiresistant. The marketed cepha-
10 poril15 IlJlve never included enterococci in the spe trum and
this n1:1 be a gnp tlut the seri cannot fill. If the spectre of
vancolTlycin-r istam staphylococci become a reality on large
C:llc. the cephalo p ril15 III Y not meet tills chaUenge either.
urrently. gents like cefotucime and ccflli.:oc ne c ntinue to
be fa t-line therapy in meningitIS, but PRP ar becoming
increasingly common and mese agents m. y n t meet this
challenge in tbe I oger tetrn. even \-vim high I' dose . The
cephalosporin series may now be nearing the end of its
e""loitable v clations but the f}-lactam f: mlly 1TI.1Y till be able to
meet the new bacterial challenges. Novc:l carbapenems •nd
rrineolS both ffcr pro pec of broader pe: tra with enhanced
anti- ram-po itive cover, which s.hould be able to in lude
cum:nc pr blems of PRP. VRE nd MR A.
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